Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

76.600
+0.7000.92%
Volume:3.17M
Turnover:237.51M
Market Cap:41.59B
PE:44.61
High:78.600
Open:76.000
Low:74.100
Close:75.900
52wk High:92.000
52wk Low:23.000
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:1.81
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.717
ROE:23.72%
ROA:4.45%
PB:9.23
PE(LYR):44.61
PS:5.48

Loading ...

Taikang Insurance Group, Inc. Increases Stake in HENLIUS (02696) by 518,500 Shares at HK$67.07 per Share

Stock News
·
Nov 25, 2025

Shanghai Henlius Biotech (2696) Announces First Patient Dosed in Phase 1 Trial of HLX13 for Unresectable HCC

Bulletin Express
·
Nov 25, 2025

HENLIUS (02696): First Patient Dosed in China for International Phase 1 Clinical Study of HLX13 (Ipilimumab Biosimilar) in First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Stock News
·
Nov 25, 2025

HK Stock Movement | HENLIUS (02696) Rises Over 6% in Afternoon Session as Serplulimab Included in NMPA's Breakthrough Therapy List

Stock News
·
Nov 24, 2025

US September Nonfarm Payrolls Exceed Expectations, Third Rate Cut This Year Unlikely

Stock News
·
Nov 21, 2025

HENLIUS (02696): Hansizhuang® (Serplulimab Injection) Combined with Chemotherapy for Gastric Cancer Neoadjuvant/Adjuvant Therapy Officially Included in NMPA's Breakthrough Therapy Designation Program

Stock News
·
Nov 20, 2025

Shanghai Henlius Biotech Receives Breakthrough Therapy Designation for HANSIZHUANG in Gastric Cancer

Reuters
·
Nov 20, 2025

Shanghai Henlius Biotech - Hansizhuang Granted Breakthrough Therapy Designation for Gastric Cancer by Nmpa

THOMSON REUTERS
·
Nov 20, 2025

Hong Kong Stocks Movement | HENLIUS (02696) Rises Over 4% as POHERDY Gains U.S. Approval, Covering All Indications of Reference Product

Stock News
·
Nov 20, 2025

Organon, Shanghai Henlius Biotech Says FDA Clears Poherdy as Pertuzumab Biosimilar

MT Newswires Live
·
Nov 17, 2025

BUZZ-Organon rises after US FDA clears first biosimilar for breast cancer

Reuters
·
Nov 17, 2025

FDA Approves Organon and Henlius' POHERDY as First Perjeta Biosimilar in US

Reuters
·
Nov 17, 2025

Henlius Biotech Gets US FDA Nod for Breast Cancer Drug's Biologics License Application

MT Newswires Live
·
Nov 14, 2025

Shanghai Henlius Biotech (2696) Announces FDA Approval of HLX11 (Pertuzumab-dpzb) for Key Breast Cancer Treatments

Bulletin Express
·
Nov 14, 2025

HENLIUS (02696): FDA Approves HLX11 (Pertuzumab, US Brand Name: POHERDY®) for HER2-Positive Early Breast Cancer Neoadjuvant/Adjuvant and Metastatic Breast Cancer Treatment

Stock News
·
Nov 14, 2025

Shanghai Henlius Biotech Inc - Approval Letter From FDA for Poherdy

THOMSON REUTERS
·
Nov 14, 2025

HK Stock Movement | HENLIUS (02696) Rises Over 4% as Denosumab Biosimilars BILDYOS and BILPREVDA Gain UK Approval

Stock News
·
Nov 13, 2025

Boyu Capital Opportunities Master Fund Increases Stake in HENLIUS (02696) by 262,500 Shares at Average Price of HK$61.28 per Share

Stock News
·
Nov 11, 2025

Boyu Capital Group Holdings Ltd. Increases Stake in HENLIUS (02696) by 80,000 Shares at Average Price of HK$61.78 per Share

Stock News
·
Nov 10, 2025

Hong Kong Stock Short Interest Data as of November 7

Stock News
·
Nov 07, 2025